CORMEDIX INC. Other Comprehensive Income (Loss), Tax
CORMEDIX INC. (CRMD) reported Other Comprehensive Income (Loss), Tax of -$25.99 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Expense Statement › Income Tax
us-gaap:OtherComprehensiveIncomeLossTax · last filed 2026-08-13
- CORMEDIX INC. other comprehensive income (loss), tax for the quarter ending 2026-06-30 was -$25.99M.
- CORMEDIX INC. other comprehensive income (loss), tax for the quarter ending 2026-03-31 was -$38.60M.
- CORMEDIX INC. other comprehensive income (loss), tax for the quarter ending 2025-12-31 was -$13.94M.
- CORMEDIX INC. other comprehensive income (loss), tax for the quarter ending 2025-09-30 was -$108.57M, a 4014.70% decline year-over-year.
- CORMEDIX INC. other comprehensive income (loss), tax for fiscal 2025 was -$162.97M, a 1008.75% decline from fiscal 2024.
- CORMEDIX INC. other comprehensive income (loss), tax for fiscal 2024 was $17.93M.
- CORMEDIX INC. other comprehensive income (loss), tax for fiscal 2022 was -$4.39K.
- CORMEDIX INC. other comprehensive income (loss), tax for fiscal 2021 was -$14.88K.
| Period end | Other Comprehensive Income (Loss), Tax 3 month | Other Comprehensive Income (Loss), Tax 3 month as first filed | Other Comprehensive Income (Loss), Tax 6 month | Other Comprehensive Income (Loss), Tax 6 month as first filed | Other Comprehensive Income (Loss), Tax 9 month | Other Comprehensive Income (Loss), Tax 12 month |
|---|---|---|---|---|---|---|
| 2026-06-30 | -$25.99M 10-Q · filed 2026-08-13 | -$64.59M 10-Q · filed 2026-08-13 | -$78.52M derived: sum of 3 quarters · filed 2026-08-13 | -$187.09M derived: sum of 4 quarters · filed 2026-08-13 | ||
| 2026-03-31 | -$38.60M 10-Q · filed 2026-05-14 | -$52.54M derived: sum of 2 quarters · filed 2026-05-14 | -$161.11M derived: sum of 3 quarters · filed 2026-05-14 | -$180.93M derived: sum of 4 quarters · filed 2026-08-13 | ||
| 2025-12-31 | -$13.94M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | -$122.51M derived: sum of 2 quarters · filed 2026-03-05 | -$142.33M derived: sum of 3 quarters · filed 2026-08-13 | -$162.97M 10-K · filed 2026-03-05 | ||
| 2025-09-30 | -$108.57M 10-Q · filed 2025-11-12 | -$128.39M derived: sum of 2 quarters · filed 2026-08-13 | -$149.03M 10-Q · filed 2025-11-12 | -$162.50M derived: sum of 4 quarters · filed 2026-08-13 | ||
| 2025-06-30 | -$19.82M 10-Q · filed 2026-08-13 | -$19.82M 10-Q · filed 2025-08-07 | -$40.46M 10-Q · filed 2026-08-13 | -$40.46M 10-Q · filed 2025-08-07 | -$53.93M derived: sum of 3 quarters · filed 2026-08-13 | -$51.15M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | -$20.64M 10-Q · filed 2026-05-14 | -$20.64M 10-Q · filed 2025-05-06 | -$34.10M derived: sum of 2 quarters · filed 2026-05-14 | -$31.33M derived: sum of 3 quarters · filed 2026-05-14 | -$17.18M derived: sum of 4 quarters · filed 2026-05-14 | |
| 2024-12-31 | -$13.47M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | -$10.69M derived: sum of 2 quarters · filed 2026-03-05 | $3.46M derived: sum of 3 quarters · filed 2026-03-05 | $17.93M 10-K · filed 2026-03-05 | ||
| 2024-09-30 | $2.77M 10-Q · filed 2025-11-12 | $16.92M derived: sum of 2 quarters · filed 2025-11-12 | $31.40M 10-Q · filed 2025-11-12 | |||
| 2024-06-30 | $14.15M 10-Q · filed 2025-08-07 | $28.63M 10-Q · filed 2025-08-07 | ||||
| 2024-03-31 | $14.48M 10-Q · filed 2025-05-06 | |||||
| 2022-12-31 | $36.97K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30 | $43.22K derived: sum of 2 quarters · filed 2023-03-30 | -$4.39K 10-K · filed 2023-03-30 | |||
| 2022-09-30 | $6.25K 10-Q · filed 2022-11-10 | -$41.36K 10-Q · filed 2022-11-10 | ||||
| 2021-12-31 | -$8.37K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30 | -$12.05K derived: sum of 2 quarters · filed 2023-03-30 | -$14.88K 10-K · filed 2023-03-30 | |||
| 2021-09-30 | -$3.68K 10-Q · filed 2022-11-10 | -$6.50K 10-Q · filed 2022-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |